



EU4Health Projects on HPV: Final Results. What's the Next?

June 12th, 2025

organized by

ISTITUTO SUPERIORE DI SANITÀ
National Center for Global Health

as part of the project

Partnership to Contrast HPV-PERCH
Grant Agreement No. 101075314



Co-funded by
the European Union

N° ID: 261D25_I

Rationale

The event, organized as part of the European project *PERCH (PartnERship to Contrast HPV)*, will be an important opportunity for exchange among institutions, professionals, and initiatives engaged in the prevention of HPV-related cancers.

PERCH partner countries* will share their national contexts and lessons learned throughout the project, offering a diverse and concrete overview of experiences across Europe. In addition, other EU-funded projects will present the outcomes of their efforts focused on HPV vaccination. The day will conclude with a high-level round table bringing together leading international experts in epidemiology, prevention, and communication to address common challenges, identify shared priorities, and outline a roadmap toward broader vaccination coverage and a coordinated strategy against HPV in Europe.

* Belgium, Czech Republic, Croatia, Estonia, France, Germany, Greece, Hungary, Italy, Lithuania, Norway, Poland, Romania, Slovak Republic, Slovenia, Spain, Sweden

Aims

The Conference aims to present and reflect on the results of the PERCH project, together with those of other EU-funded initiatives focused on HPV prevention. By valuing the diversity of national experiences, it seeks to promote mutual learning, encourage the convergence of strategies, and contribute to the development of a shared European commitment to reducing the burden of HPV-related cancers through a comprehensive approach that includes vaccination, screening, and all key steps in the continuum of prevention.

Working method

Reports, round table and general discussion.





PROGRAMME

- 10.00 Registration & Welcome Coffee
- 10.30 Welcome and Introduction
Rocco Bellantone, President of the Italian National Institute of Health
Maria Rosaria Campitiello, Head of the Department for Prevention, Research and Health Emergencies of the Ministry of Health (*to be confirmed*)

Chairpersons: **Raffaella Bucciardini**, PERCH Coordinator
Urška Ivanuš, PERCH WP2 Leader

- 10.45 PERCH Countries Sharing
- *Existing practices for high HPV vaccination coverage*
- *Relevant PERCH activities and results*

Croatia: **Ivana Andrijasevic**
Czech Republic: **Lenka Vostalová**
Estonia: **Merilin Vernik**
France: **Magid Herida**
Germany: **Miriam Gerlich**
Greece: **Anastasia Balasopoulou**
Hungary: **Péter Csizmadia**
Italy: **Michele Conversano**
Lithuania: **Rasa Liausediene**
Norway: **Lill-Iren Schou Trogstad**
Poland: **Ewa Augustynowicz**
Slovakia: **Daniela Kállayová**
Slovenia: **Elizabeta Radelj Pepevnik**
Spain: **Maria Brotons Agulló**
Sweden: **Madelene Danielsson**

- 13.10 Light Lunch

- 14.00 DGSANTE Representative
Presentation
Philippe Roux

- 14.15 HaDEA Representative
Presentation
Chiara Tripepi

Chairperson: **Elizabeta Radelj Pepevnik**

- 14.30 Part 1 – Experiences from EU-funded HPV Projects
Projects: *PROTECT-EUROPE*
Alberto Hermosel, Silvia Romeo
RIVER Project
Janine de Zeeuw



15.00 Break

Chairpersons: **Raffaella Bucciardini, Urška Ivanuš**

15.10 Part 2 – Round Table with HPV Experts
Discussion on communication gaps and next steps toward a Community of Practice

Participants: **Marc Arbyn, Silvia Franceschi, Jiayao Lei, Dorte Raben, Isabel Mosquera Metcalfe, Kirsty Roy, Marcin Rozwadowski, Alex Vorsters, Wendy Yared**

Scientific Board PERCH:
Paul Bloem, Rui Medeiros, Siff Malue Nielsen, Roberta Pastore

17.00 Closing Remarks

17.15 End of the meeting

SPEAKERS, CHAIRPERSONS and ROUND TABLE SPEAKERS

Ivana Andrijasevic - Croatian Institute of Public Health, Zagreb (Croatia)
Marc Arbyn - Sciensano, Brussels (Belgium)
Ewa Augustynowicz - National Institute of Public Health, National Research Institute, Warsaw (Poland)
Anastasia Balasopoulou - 1st Regional Health Authority of Attica, Athens, (Greece)
Paul Bloem - World Health Organization, Geneva (Switzerland)
Maria Brotons Agulló - Catalan Institute of Oncology, Barcelona (Spain)
Raffaella Bucciardini - Istituto Superiore di Sanità, Rome (Italy)
Michele Conversano - ASL Taranto, Taranto (Italy)
Péter Csizmadia - National Center for Public Health and Pharmacy, Budapest (Hungary)
Madelene Danielsson - Public Health Agency of Sweden, Solna (Sweden)
Silvia Franceschi - Centro di riferimento oncologico di Aviano IRCCS, Aviano (PN) (Italy)
Miriam Gerlich - Federal Institute of Public Health, Cologne (Germany)
Magid Herida - Ministry of Health and Prevention, Paris (France)
Alberto Hermosel - European Cancer Organisation, Brussels (Belgium)
Urška Ivanuš - Institute of Oncology Ljubljana, Ljubljana (Slovenia)
Daniela Kállayová - Ministry of Health of the Slovak Republic, Bratislava (Slovakia)
Jiayao Lei - Karolinska Institute, Stockholm (Sweden)
Rasa Liausediene - National Public Health Center under The Ministry of Health of the Republic of Lithuania, Vilnius (Lithuania)
Rui Medeiros - Portuguese Institute of Oncology, (IPO-Porto), Porto (Portugal)
Isabel Mosquera Metcalfe - International Agency for Research on Cancer (IARC), Lyon (France)
Siff Malue Nielsen - World Health Organization, Copenhagen (Denmark)
Roberta Pastore - World Health Organization, Copenhagen (Denmark)
Dorte Raben - Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen (Denmark)
Elizabeta Radelj Pepevnik - Institute of Oncology Ljubljana, Ljubljana (Slovenia)
Silvia Romeo - European Cancer Organisation, Brussels (Belgium)
Philippe Roux - European Commission DG SANTE, Luxembourg City (Luxembourg)
Kirsty Roy - Public Health Scotland, Edinburgh (Scotland)
Marcin Rozwadowski - Centre of Postgraduate Medical Education, Warsaw (Poland)



Lill-Iren Schou Trogstad - Norwegian Institute of Public Health, Oslo (Norway)
Chiara Tripepi - European Health and Digital Executive Agency (HaDEA), Brussels (Belgium)
Merilin Vernik - Estonian Health Board, Tallinn (Estonia)
Lenka Vostalová - Institute of Health Information and Statistics of the Czech Republic, Prague (Czech Republic)
Alex Vorsters - University of Antwerp, Antwerp (Belgium)
Wendy Yared - Association of European Cancer Leagues, Brussels (Belgium)
Janine de Zeeuw - University Medical Center Groningen (UMCG), Groningen (the Netherlands)

Scientific Coordinator

RAFFAELLA BUCCIARDINI
Director Health Equity Unit
National Center for Global Health
Istituto Superiore di Sanità
tel: +39 06 4990.6577
e-mail: raffaella.bucciardini@iss.it

Scientific Secretariat

ANNA MARIA GIAMMARIOLI
National Center for Global Health
Istituto Superiore di Sanità
tel. +39 06 4990.3645
e-mail: annamaria.giammarioli@iss.it

Organizing Secretariat

HEALTHDATA CONSULTING S.r.l.
Via Morghen, 27, Torino
tel. + 39 011 0267950
eventi@hdcons.it
www.hdcons.it

Technical Moderator

CARLO ARAGONA
Cleverage srl
Via Francesco Datini, 5, Roma
+39 06 58209714
+39 339 3419287
www.cleverage.it
www.siamoindiretta.it

GENERAL INFORMATION

The event will take place in a hybrid mode.

Meeting venue: Auditorium Pocchiari, Istituto Superiore di Sanità
Viale Regina Elena, 299 - Rome

Online: Microsoft Teams platform.



**Official language**

The official language is English. Simultaneous translation will not be available.

Target audience

The conference is intended for health care personnel and research organizations and institutions interested in the prevention of diseases related to HPV infection.

A maximum of 200 on-site attendees and up to a maximum of 1000 remote users will be admitted.

Registration and participation

Participation in the event is free of charge.

To register, please, complete online and **submit by 8 June 2025** the form available at the following link: <https://forms.office.com/e/JiHewS6Bbt> .

In the application form, applicants must express their preference to participate in-person or remotely.

Those who have expressed preference to participate on-site will be selected on a first-come first-served basis. Only those who are notified will be admitted on-site. Their attendance will be noted by recording entry and exit on the appropriate attendance register.

Participants who have expressed preference to follow the event remotely will receive via e-mail the link to the meeting and the related instructions. Attendance of online participants will be detected by checking the connection logs. It is therefore recommended to specify first and last name in full when connecting to the videoconferencing platform. The absence of these identifying data will not allow the detection of attendance at the event and the subsequent issuance of the certificate.

All participants, whether in attendance or remotely, will be submitted a satisfaction online questionnaire.

Certificates

Upon request, participants who have attended for at least 75% of the duration of the event and completed the satisfaction online questionnaire will be issued a certificate of attendance, which will be sent by e-mail.

This event does not provide any CME credits.

For any further information about the conference, please contact the Organizing Secretariat.